LONCASTUXIMAB TESIRINE for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 23 adverse event reports in the FDA FAERS database where LONCASTUXIMAB TESIRINE was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for LONCASTUXIMAB TESIRINE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 12 | 14.0% | 6 | 1 |
| Pneumonia | 8 | 9.3% | 5 | 8 |
| Anaemia | 7 | 8.1% | 1 | 5 |
| Platelet count decreased | 7 | 8.1% | 0 | 7 |
| Covid-19 | 6 | 7.0% | 5 | 5 |
| Thrombocytopenia | 6 | 7.0% | 1 | 4 |
| Gamma-glutamyltransferase increased | 5 | 5.8% | 0 | 5 |
Other Indications for LONCASTUXIMAB TESIRINE
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
POLATUZUMAB VEDOTIN-PIIQ (158)
GEMCITABINE (147)
LENALIDOMIDE (143)